Teriparatide Dosing Regimen
Administer teriparatide 20 mcg subcutaneously once daily into the thigh or abdomen for a maximum of 2 years, followed by antiresorptive therapy to maintain bone gains. 1
Dose and Route
The FDA-approved dose is 20 mcg given subcutaneously once daily 1. This dose has demonstrated robust fracture reduction in clinical trials, decreasing vertebral fractures by 65% and nonvertebral fractures by 35% in postmenopausal women 2. The subcutaneous injection should be administered into the thigh or abdominal region 1.
Frequency and Timing
While the standard regimen is daily administration 1, emerging evidence suggests timing may influence efficacy. One study found that morning administration (08:00) resulted in a 9.1% increase in lumbar spine BMD versus 4.8% with evening dosing after 12 months 3. This difference likely relates to circadian rhythms in bone turnover markers. However, this remains investigational, and the FDA label does not specify optimal timing 1.
Alternative dosing schedules exist in some regions: Japanese studies have evaluated 56.5 mcg once weekly and 28.2 mcg twice weekly 4, but these are not FDA-approved regimens in the United States.
Treatment Duration
The maximum recommended lifetime exposure is 2 years 1. This limitation stems from rat toxicology studies showing increased osteosarcoma risk with lifelong exposure, though no increased human risk has been observed in over 1 million users since 2002 5. The FDA label states that use beyond 2 years "should only be considered if a patient remains at or has returned to having a high risk for fracture" 1.
The anabolic effects of teriparatide are maximal in the first 6 months when bone formation exceeds resorption most dramatically 6. Benefits are evident by 3 months and continue throughout the treatment period 1.
Sequential Therapy: Critical Component
Antiresorptive therapy must follow teriparatide to maintain bone gains 5. The Endocrine Society strongly recommends (Grade 1|⊕⊕◯◯) that patients completing teriparatide receive subsequent treatment with bisphosphonates, denosumab, raloxifene, or hormone therapy 5. Without this sequential approach, most anabolic effects dissipate within one year of discontinuation 5.
The American College of Physicians confirms this approach with high-certainty evidence showing that romosozumab followed by alendronate reduces hip fractures, clinical vertebral fractures, and all clinical fractures compared to bisphosphonate alone 2. While this evidence is specific to romosozumab, the principle applies to all anabolic agents.
Supplementation Requirements
All patients require calcium (1000-1500 mg/day) and vitamin D (800-1200 IU/day) supplementation 1. The FDA label explicitly instructs clinicians to ensure adequate supplementation if dietary intake is insufficient 1.
Administration Precautions
Initial doses should be given under circumstances where the patient can sit or lie down due to orthostatic hypotension risk 1. Patients should be instructed to remain seated or recumbent if they experience lightheadedness or palpitations after injection 1.
The medication requires refrigeration at 2°C to 8°C (36°F to 46°F) at all times 1. Doses should be administered immediately after removal from refrigeration, and the pen must never be frozen 1.
Patient Selection
Teriparatide is indicated for patients at very high fracture risk, specifically those with severe or multiple vertebral fractures 5. The Endocrine Society provides a Grade 1|⊕◯◯◯ recommendation for this population. It is also appropriate for patients who have failed or are intolerant to other osteoporosis therapies 1.
Contraindications and Avoidance
Do not use teriparatide in patients with:
- Open epiphyses (pediatric/young adults) 1
- Paget's disease or other metabolic bone diseases 1
- Bone metastases or skeletal malignancies 1
- Prior skeletal radiation therapy 1
- Pre-existing hypercalcemia 1
- Active urolithiasis (use with caution) 1
Common Pitfalls
Failing to initiate antiresorptive therapy after completing teriparatide is the most critical error, as bone gains rapidly dissipate without sequential treatment 5.
Prior bisphosphonate use may blunt teriparatide's anabolic response, though the VERO trial demonstrated similar fracture reductions in prior bisphosphonate users versus treatment-naïve patients 5. The onset may be delayed and magnitude somewhat reduced, but efficacy is maintained 5.
Concurrent bisphosphonate use with teriparatide should be avoided, as combination therapy does not enhance and may diminish the anabolic effect 7.
Monitoring
Assess serum calcium before initiating therapy and monitor for hypercalcemia, particularly in the first months of treatment 1. Common adverse effects include nausea, dizziness, headache, palpitations, and leg cramps, which led to treatment discontinuation in 17 more patients per 1000 compared to placebo 2.